Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology
JAMA Internal Medicine · 01.11.2024 · 184 (11) · 1290
DOI: 10.1001/jamainternmed.2024.4346 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA Internal Medicine, erschienen am 01.11.2024. Verfasst von Thomas A Wadden und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Glucagon-Like Peptides, Obesity. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Obesity is associated with numerous psychosocial complications, making psychiatric safety a consideration for treating people with obesity. Few studies have investigated the psychiatric safety of newly available antiobesity medications.
Objective
To evaluate the psychiatric safety of subcutaneous semaglutide, 2.4 mg, once weekly in people without known major psychopathology. Design, Setting, and Participants This post hoc analysis of pooled data from the randomized, double-blind, placebo-controlled, multicenter phase 3a STEP 1, 2, and 3 trials (68 weeks; 2018-2020) and phase 3b STEP 5 trial (104 weeks; 2018-2021) included adults with overweight or obesity; STEP 2 participants also had type 2 diabetes. Trial designs have been published previously.
Interventions
Semaglutide, 2.4 mg, vs placebo. Main Outcomes and Measures Depressive symptoms and suicidal ideation/behavior were assessed using the Patient Health Questionnaire (PHQ-9) and Columbia–Suicide Severity Rating Scale, respectively. Psychiatric and nervous system disorder adverse events were investigated.
Results
This analysis included 3377 participants in the STEP 1, 2, and 3 trials (2360 women [69.6%]; mean [SD] age, 49 [13] years) and 304 participants in STEP 5 (236 women [77.6%]; mean [SD] age, 47 [11] years). In the STEP 1, 2, and 3 trials, mean (SD) baseline PHQ-9 scores for the semaglutide, 2.4 mg, and placebo groups were 2.0 (2.3) and 1.8 (2.3), respectively, indicating no/minimal symptoms of depression. PHQ-9 scores at week 68 were 2.0 (2.9) and 2.4 (3.3), respectively; the estimated treatment difference (95% CI) between groups was −0.56 (−0.81 to −0.32) ( P < .001). Participants treated with semaglutide vs placebo were less likely to shift (from baseline to week 68) to a more severe category of PHQ-9 depression (odds ratio, 0.63; 95% CI, 0.50-0.79; P < .001). Based on the Columbia–Suicide Severity Rating Scale, 1% or fewer of participants reported suicidal ideation/behavior during treatment, with no differences between semaglutide, 2.4 mg, and placebo. Psychiatric disorder adverse events were generally balanced between groups. Similar results were observed in STEP 5. Conclusions and Relevance The results of this post hoc analysis suggest that treatment with semaglutide, 2.4 mg, did not increase the risk of developing symptoms of depression or suicidal ideation/behavior vs placebo and was associated with a small but statistically significant reduction in depressive symptoms (not considered clinically meaningful). People with obesity should be monitored for mental health concerns so they can receive appropriate support and care. Trial Registration ClinicalTrials.gov Identifiers: STEP 1 ( NCT03548935 ), 2 ( NCT03552757 ), 3 ( NCT03611582 ), and 5 ( NCT03693430 )
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Novo Nordisk A/S, Søborg, Denmark.
- Novo Nordisk Inc, Plainsboro, New Jersey.
- Department of Medicine and Medical Education, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
- Cleveland Clinic London Hospital, Portland Place Outpatient Centre, London, England.
- Mental Health Centre Copenhagen and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Zitieren
APA
Wadden, T. A., Brown, G. K., Egebjerg, C., Frenkel, O., Goldman, B., Kushner, R. F., McGowan, B., Overvad, M., & Fink-Jensen, A. (2024). Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology. JAMA Internal Medicine, 184(11), 1290. https://doi.org/10.1001/jamainternmed.2024.4346
Vancouver
Wadden TA, Brown GK, Egebjerg C, Frenkel O, Goldman B, Kushner RF, et al. Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology. JAMA Internal Medicine. 2024;184(11):1290. doi:10.1001/jamainternmed.2024.4346
BibTeX
@article{Wadden2024,
author = {Wadden, Thomas A and Brown, Gregory K and Egebjerg, Christina and Frenkel, Ofir and Goldman, Bryan and Kushner, Robert F and McGowan, Barbara and Overvad, Maria and Fink-Jensen, Anders},
title = {Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology},
journal = {JAMA Internal Medicine},
year = {2024},
volume = {184},
number = {11},
pages = {1290},
doi = {10.1001/jamainternmed.2024.4346}
}
EUVIMED